The TransCon CNP, a prodrug for achondroplasia
2017-04-09Research
Ascendis Pharma is developing a drug for achondroplasia, using new technology that combines the benefits of a pro-drug and sustained-release technologies. Learn more about TransCon CNP here.
A challenging report on Vosoritide
2016-11-23Research
Although BioMarin's results for Vosoritide have been mostly positive, there are some concerns regarding the less positive results.
BioMarin presents report on phase 2 study of Vosoritide
2016-10-20Research
BioMarin has issued a new press release with data on the phase 2 clinical trial for Vosoritide, during the ASHG 2016 meeting. Read all about it here.
State of the art in achondroplasia
2016-06-30Research
This is a summary of the current state of drug development in achondroplasia.
BMN-111 Phase 2: study 111-202 and extension study 111-205
2016-05-13Research
There are two studies by BioMarin in Phase 2 clinical trials where BMN-111 (vosoritide) is being administered. They have different objectives and durations, which can be consulted here.
Update in multicenter study from BioMarin
2016-04-21Research
Biomarin is sponsoring and coordinating a study for the study of growth patterns of Achondroplasia in children and adolescents in several centers in Europe and North America. Find out where it's being conduced here.